109 related articles for article (PubMed ID: 12029262)
1. The role of antithrombin III in critical patients in obstetrics.
Mangione S; Giarratano A
Minerva Anestesiol; 2002 May; 68(5):449-53. PubMed ID: 12029262
[TBL] [Abstract][Full Text] [Related]
2. [Plasma concentration of biochemical markers in pre-eclampsia-eclampsia and its association with the severity of the disease].
Chavarría Olarte ME; González Gleason A; Lara González AL; Sojo Aranda I; García Paleta Y; Vital Reyes VS; Reyes Fuentes A
Ginecol Obstet Mex; 2000 Sep; 68():385-93. PubMed ID: 11080945
[TBL] [Abstract][Full Text] [Related]
3. [Antithrombin-III in preeclampsia-eclampsia. Pilot study].
Verduzco Rodríguez L; González Puebla E; López Ariza B; Manffrini Madrid F
Ginecol Obstet Mex; 1998 Aug; 66():343-6. PubMed ID: 9745197
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure.
Eisele B; Lamy M
Semin Thromb Hemost; 1998; 24(1):71-80. PubMed ID: 9515782
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of AT in pre-eclampsia: a case-control prospective trial.
Paternoster DM; Fantinato S; Manganelli F; Milani M; Nicolini U; Girolami A
Thromb Haemost; 2004 Feb; 91(2):283-9. PubMed ID: 14961155
[TBL] [Abstract][Full Text] [Related]
6. Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis.
Moubarak P; Zilker S; Wolf H; Hofner B; Kneib T; Küchenhoff H; Jauch KW; Hartl WH
Shock; 2008 Dec; 30(6):634-41. PubMed ID: 18520701
[TBL] [Abstract][Full Text] [Related]
7. Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study.
Aibiki M; Fukuoka N; Nishiyama T; Maekawa S; Shirakawa Y
Shock; 2007 Aug; 28(2):141-7. PubMed ID: 17515857
[TBL] [Abstract][Full Text] [Related]
8. Antithrombin III in hematopoietic stem cell transplantation.
Haire WD
Semin Thromb Hemost; 1997; 23(6):591-601. PubMed ID: 9469635
[TBL] [Abstract][Full Text] [Related]
9. Coagulation inhibitors in preeclamptic pregnant women.
Osmanağaoğlu MA; Topçuoğlu K; Ozeren M; Bozkaya H
Arch Gynecol Obstet; 2005 Mar; 271(3):227-30. PubMed ID: 14735372
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of maternal and perinatal outcomes in Taiwanese women with complete and partial HELLP syndrome and women with severe pre-eclampsia without HELLP.
Liu CM; Chang SD; Cheng PJ; Chao AS
J Obstet Gynaecol Res; 2006 Dec; 32(6):550-8. PubMed ID: 17100816
[TBL] [Abstract][Full Text] [Related]
11. [Expression and its clinical significance of tissue factor pathway inhibitor and antithrombin-III in patients with hepatic inflammatory diseases].
Dong L; Peng Y; Wang R
Zhonghua Gan Zang Bing Za Zhi; 1999 Dec; 7(4):224-5. PubMed ID: 10715793
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin III. Key factor in extracorporeal circulation.
Ranucci M
Minerva Anestesiol; 2002 May; 68(5):454-7. PubMed ID: 12029263
[TBL] [Abstract][Full Text] [Related]
13. The relationship between pregnancy induced hypertension and congenital thrombophilia.
Demir SC; Evruke C; Ozgunen T; Kadayifci O; Altintas U; Kokangul S
Saudi Med J; 2006 Aug; 27(8):1161-6. PubMed ID: 16883445
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin III in animal models of sepsis and organ failure.
Dickneite G
Semin Thromb Hemost; 1998; 24(1):61-9. PubMed ID: 9515781
[TBL] [Abstract][Full Text] [Related]
15. [Dynamics of thrombin-antithrombin-III complex (TAT-III) and prothrombin fragments F1 + 2 during labour with and without aprotinin administration].
Kühnert M; Stein W; Woernle F; Tekesin I; Hellmeyer L; Schmidt S
Z Geburtshilfe Neonatol; 2004 Jun; 208(3):98-109. PubMed ID: 15229817
[TBL] [Abstract][Full Text] [Related]
16. [Changes in antithrombin III concentration in gestosis patients].
Huber H; Brehm R
Z Geburtshilfe Perinatol; 1984; 188(5):223-5. PubMed ID: 6506835
[TBL] [Abstract][Full Text] [Related]
17. [Circadian blood pressure rhythm in preeclampsia as a predictor of maternal and obstetrical outcome].
Munz W; Seufert R; Steiner E; Pollow K; Brockerhoff P
Z Geburtshilfe Neonatol; 2003; 207(4):132-6. PubMed ID: 14528415
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Sayin M; Varol FG; Sayin NC
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):183-7. PubMed ID: 15893867
[TBL] [Abstract][Full Text] [Related]
19. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
[TBL] [Abstract][Full Text] [Related]
20. [Effect of antithrombin-III (AT-III) on intestinal epithelium changes related to obstructive icterus: experimental study in rats].
Caglikulekci M; Dirlik M; Scatton O; Cinel I; Ozer I; Cinel L; Ocal K; Aydin S
Ann Chir; 2004 Jun; 129(5):273-7. PubMed ID: 15220100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
